- Previous Close
2,621.65 - Open
2,615.00 - Bid 2,480.05 x --
- Ask 2,492.80 x --
- Day's Range
2,475.00 - 2,639.20 - 52 Week Range
2,049.75 - 3,485.75 - Volume
5,945 - Avg. Volume
4,754 - Market Cap (intraday)
311.125B - Beta (5Y Monthly) 0.25
- PE Ratio (TTM)
34.80 - EPS (TTM)
71.57 - Earnings Date Apr 30, 2025 - May 5, 2025
- Forward Dividend & Yield 54.00 (2.06%)
- Ex-Dividend Date Nov 6, 2024
- 1y Target Est
3,031.73
Ajanta Pharma Limited, a specialty pharmaceutical formulation company, together with its subsidiaries, develops, manufactures, and markets speciality pharmaceutical finished dosages. The company markets and serves various therapeutic segments, such as cardiology, antidiabetic, ophthalmology, dermatology, pain management, and respiratory areas. It also provides tablets, capsules, injectables, inhalers, ointments, creams, and liquids. The company serves in India, Africa, rest of Asia, the United States, and internationally. Ajanta Pharma Limited was founded in 1973 and is headquartered in Mumbai, India.
www.ajantapharma.com8,073
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AJANTPHARM.BO
View MorePerformance Overview: AJANTPHARM.BO
Trailing total returns as of 4/4/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AJANTPHARM.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AJANTPHARM.BO
View MoreValuation Measures
Market Cap
327.48B
Enterprise Value
320.23B
Trailing P/E
36.63
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.33
Price/Book (mrq)
8.91
Enterprise Value/Revenue
7.14
Enterprise Value/EBITDA
23.68
Financial Highlights
Profitability and Income Statement
Profit Margin
19.81%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
45.32B
Net Income Avi to Common (ttm)
8.98B
Diluted EPS (ttm)
71.57
Balance Sheet and Cash Flow
Total Cash (mrq)
7.42B
Total Debt/Equity (mrq)
0.89%
Levered Free Cash Flow (ttm)
--